Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05470595 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Study acronym: LCNEC-ALPINE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Site details revised at 2 of 15 sitesv5
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 15 of 15 sites
    v4
  4. Study sites: 14 to 15v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Trial Details
NCT Number NCT05470595
Lead Sponsor Technische Universität Dresden
Collaborators: Roche Pharma AG
Conditions
(from sponsor)		 Large Cell Neuroendocrine Carcinoma of the Lung
Related terms Carcinoma, Neuroendocrine, Lung Neoplasms
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov